KLRS

Business Context and Reporting Period

Kalaris Therapeutics, Inc. (KLRS) is a clinical-stage biopharmaceutical company focused on developing TH103, a novel anti-VEGF drug for retinal diseases. This Form 10-Q covers the quarterly period ended June 30, 2026. The company operates as a single segment and is currently in the development phase with no commercial product sales. Following a reverse merger with AlloVir, Inc. in March 2025, the company trades on the Nasdaq Global Market.

Key Financial Metrics

Note: The company has no debt obligations outstanding as of June 30, 2026, following the conversion of prior convertible notes in the 2025 Merger.

Material Changes vs. Prior Period

• Increased R&D Spend: R&D expenses rose by $2.1 million (14.6%) year-over-year, driven by a $3.3 million increase in clinical trial and CRO costs as the company enrolled patients in its Phase 1b/2 trial, partially offset by a decrease in manufacturing costs.
• Decreased G&A Spend: G&A expenses declined by $0.5 million, primarily due to a one-time $1.5 million directors' and officers' insurance charge in the prior year related to the Merger, which was not repeated in the current period.
• Elimination of Non-Cash Interest/Derivative Costs: The prior period included significant non-cash expenses related to the fair value changes of derivative liabilities and tranche liabilities associated with convertible notes. These liabilities were extinguished upon the Merger in March 2025, resulting in zero such expenses in the current period.
• Investing Activities: The company utilized $30.2 million in cash for investing activities in the current period, primarily for the purchase of marketable securities, whereas the prior period had no investing cash flows.

Guidance, Outlook, and Risks

Outlook and Clinical Progress:

• The company announced positive additional data from its Phase 1a single-ascending dose (SAD) trial in July 2026, showing robust visual acuity improvements and extended intraocular retention.
• A Phase 1b/2 multiple ascending dose trial is ongoing, with preliminary data expected in the first half of 2027.
• Management expects to initiate Phase 3 trials by year-end 2027, assuming successful Phase 1b/2 results.

Liquidity and Capital Resources:

• As of June 30, 2026, the company held $93.5 million in cash, cash equivalents, and marketable securities.
• Management estimates these funds are sufficient to operate into the fourth quarter of 2027.
• The company has an effective shelf registration statement (Form S-3) and an At-the-Market (ATM) sales agreement with TD Cowen for up to $100 million, though no shares have been sold under the ATM as of June 30, 2026.

Material Risks and Contingencies:

• Internal Controls: The company has identified material weaknesses in its internal control over financial reporting that remain unremediated as of June 30, 2026. Management is implementing new ERP systems and hiring additional accounting personnel to address these issues.
• Manufacturing and Safety: The company has observed cases of intraocular inflammation (IOI) in clinical trials, potentially linked to impurities in the manufacturing process. While process adjustments have reduced impurities, the risk of future IOI or manufacturing delays remains.
• Regulatory and Legal: The company faces risks related to FDA regulatory changes, including potential workforce reductions at the agency. Two shareholder lawsuits regarding the Merger were voluntarily dismissed in April 2026.
• Related Party Obligations: A $32.1 million royalty obligation to Samsara BioCapital (a related party) is recorded as a long-term liability, contingent on future commercial sales.

Investor Verification Checklist

• Cash Runway: Verify the accuracy of the $93.5 million cash balance and the projection that funds will last into Q4 2027, given the high burn rate of ~$22.6 million per six months.
• Internal Control Remediation: Monitor progress reports on the remediation of material weaknesses in internal controls, as failure to remediate could lead to restatements or loss of investor confidence.
• Manufacturing Impurities: Track updates on the manufacturing process refinements intended to eliminate intraocular inflammation (IOI) observed in clinical trials.
• Phase 1b/2 Timeline: Confirm the timeline for the release of preliminary Phase 1b/2 data (expected H1 2027) and the subsequent decision to proceed to Phase 3.
• Capital Raising: Watch for announcements regarding the utilization of the ATM facility or new equity/debt financings, as the company will require substantial additional funding before profitability.